Table 2 ROR, PRR, BCPNN, and MGPS methods, formulas, and thresholds.

From: A pharmacovigilance study of thromboembolism events associated with vascular endothelial growth factor receptor tyrosine kinase inhibitors based on FAERS database

Method

Formula

Threshold

ROR

\(\:ROR=\frac{a/c}{b/d}=\frac{ad}{bc}\)

a ≥ 3, lower limit of 95% CI > 1

\(\:\text{S}E\left(lnROR\right)=\sqrt{\frac{1}{a}+\frac{1}{b}+\frac{1}{c}+\frac{1}{d}}\)

\(\:{95\text{\%}\:\text{C}\text{I}=e}^{lnROR\pm\:1.96SE\left(\text{l}\text{n}ROR\right)}\)

PRR

\(\:PRR=\frac{a/(a+b)}{b/(c+d)}\)

a ≥ 3, PRR ≥ 2, χ2  ≥ 4

\(\:SE\left(lnPRR\right)=\sqrt{\frac{1}{a}-\frac{1}{a+b}+\frac{1}{c}-\frac{1}{c+d}}\)

\(\:{95\%CI=e}^{lnPRR\pm\:1.96SE\left(lnPRR\right)}\)

\(\:{}^{2}=\frac{{(\left|ad-bc\right|-\frac{N}{2})}^{2}N}{(a+b)(c+d)(a+c)(b+d)}\)

BCPNN

\(\:IC={\text{log}}_{2}\frac{a(a+b+c+d)}{(a+b)(a+c)}\)

IC-2SD > 0

\(\:E\left(IC\right)={\text{log}}_{2}\frac{(a+\gamma\:11)(a+b+c+d+\alpha\:)(a+b+c+d+\beta\:)}{(a+b+c+d+\gamma\:)(a+b+\alpha\:1)(a+c+\beta\:1)}\)

\(\:V\left(IC\right)=\frac{1}{{\left(ln2\right)}^{2}}\left\{\left[\frac{\left(a+b+c+d\right)-a+\gamma\:-\gamma\:11}{(a+\gamma\:11)(1+a+b+c+d+\gamma\:)}\right]+\left[\frac{\left(a+b+c+d\right)-\left(a+b\right)+\alpha\:-\alpha\:1}{(a+b+\alpha\:1)(1+a+b+c+d+\alpha\:)}\right]+\left[\frac{\left(a+b+c+d\right)-\left(a+c\right)+\beta\:-\beta\:1}{(a+c+\beta\:1)(1+a+b+c+d+\beta\:)}\right]\right\}\)

\(\:\alpha\:={\upalpha\:}1+\alpha\:2\)

\(\:\beta\:=\beta\:1+\beta\:2\)

\(\:\gamma\:={\upgamma\:}11\frac{(a+b+c+d+\alpha\:)(a+b+c+d+\beta\:)}{(a+b+\alpha\:1)(a+c+\beta\:1)}\)

\(\:IC-2SD=E\left(IC\right)-2\sqrt{V\left(IC\right)}\)

MGPS

\(\:EBGM=\frac{a(a+b+c+d)}{(a+c)(a+b)}\)

EBGM05 > 2

\(\:\text{S}E\left(lnEBGM\right)=\sqrt{\frac{1}{a}+\frac{1}{b}+\frac{1}{c}+\frac{1}{d}}\)

\(\:{95\text{\%}\:\text{C}\text{I}=e}^{lnEBGM\pm\:1.96SE\left(\text{l}\text{n}EBGM\right)}\)